ARS Pharmaceuticals Inc · Q4 2023 earnings

Briefing

ARS Pharmaceuticals reported fourth quarter and full year 2023 financial results and provided a business update.

ARS Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighting the submission of response to the FDA's CRL for neffy in early Q2 2024 and successful completion of neffy repeat dose nasal allergen challenge study. The company ended the quarter with $228.4 million in cash, cash equivalents and short-term investments.

• Preparing to submit response to the FDA’s CRL for neffy in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period
• In Phase 2 urticaria clinical trial, neffy met primary endpoints and showed rapid symptom control; planning to initiate outpatient study later in 2024, potentially followed by initiation of a single pivotal efficacy study
• Ended fourth quarter with $228.4 million in cash, cash equivalents and short-term investments with an expected operating runway of at least three years
• Well-capitalized to support anticipated H2 2024 launch of neffy in the U.S.

Headline financials

Revenue & EPS history

ARS Pharma plans to submit its response to the FDA’s CRL early in the second quarter of 2024, with an anticipated FDA action date and launch of neffy, if approved, in the second half of 2024. They also plan to initiate an outpatient urticaria study later in 2024, potentially followed by initiation of a single pivotal efficacy study.